Clinical trial
Carboplatin and Pemetrexed in Recurrent Platinum Sensitive Ovarian Cancer
NCT00230542 · Dana-Farber Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00230542 |
|---|---|
| Title | Carboplatin and Pemetrexed in Recurrent Platinum Sensitive Ovarian Cancer |
| Official title | Phase II Study of Carboplatin and Pemetrexed in Patients With Recurrent Platinum Sensitive Ovarian, Fallopian Tube or Primary Peritoneal Cancer |
| Lead sponsor | Dana-Farber Cancer Institute, Other |
| Collaborators | Massachusetts General Hospital Brigham and Women's Hospital |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer |
| Intervention type | Drug |
| Interventions | Carboplatin, Pemetrexed |
| Enrollment | 44 |
| Start date | Sep 1, 2005 |
| Primary completion | Jul 1, 2007 |
| Completion | Apr 1, 2011 |
| First posted | Oct 3, 2005 |
| Last update posted | Aug 13, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: